CD274 and non-small cell lung carcinoma: The DETERRED – part II trial is a single institution phase II trial assessing the safety and feasibility of simultaneous PD-L1 blockade with atezolizumab and concurrent CRT followed by consolidation full dose carboplatin/paclitaxel (CP) with atezolizumab and maintenance atezolizumab up to 1 year for locally advanced NSCLC.